๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical cooperative trials of the national cancer institute of Canada clinical trials group breast cancer site group

โœ Scribed by Kathleen I. Pritchard

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
621 KB
Volume
74
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Venous thromboembolism and nonsmall cell
Venous thromboembolism and nonsmall cell lung cancer : A pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials
โœ Lisa K. Hicks; Matthew C. Cheung; Keyue Ding; Baktiar Hasan; Lesley Seymour; Aur ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 174 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND: Advanced nonsmall cell lung cancer (NSCLC) is associated with venous thromboembolism (VTE). However, to the authors' knowledge, the incidence of VTE in early NSCLC, predictors of VTE, and the prognostic significance of VTE in NSCLC have not been explored. ## METHODS: I

Completion rates in health-related quali
Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group
โœ David Osoba; Benny Zee ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 143 KB ๐Ÿ‘ 2 views

The approach of the National Cancer Institute of Canada Clinical Trials Group to measuring compliance, that is, completion rates, for health-related quality of life questionnaires is presented. Completion rates can be measured at the institutional, patient, questionnaire and item levels for baseline

Current NCI-sponsored Cooperative Group
Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancer
โœ Jennifer Eng-Wong; Jo Anne Zujewski ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 99 KB ๐Ÿ‘ 2 views

Over several decades, investigators working through National Cancer Institute-sponsored Cooperative Groups have contributed to major advances in the endocrine treatment of breast cancer. Accomplishments include the benefit of tamoxifen therapy for early stage invasive and noninvasive breast cancer,